Table 2.
Antiviral efficacies and mechanisms of re-identified early and late HBV life cycle inhibitors.
| Name | %Imax | EC50 | CC50 | TI | Inhibitor published PMID | Mechanism published PMID | Target/proposed mechanism | |
|---|---|---|---|---|---|---|---|---|
| p1 inhibitor |
LE 135 |
94.5 |
11.68 |
>25 |
>2.2 |
25550158 |
RARβ |
|
| p2 inhibitor | Nocodazole | 91.8 | 1.06 | >25 | >23.7 | 28878350 | Microtubuli | |
| Vincristine | 96.9 | 1.27 | >25 | >19.6 | 28878350 | |||
| Floxuridine | 97.6 | 1.53 | >25 | >16.4 | 31247245 | Different steps in nucleic acid synthesis | ||
| Decitabine | 91.9 | 1.33 | >25 | >18.8 | 31247245 | |||
| GS-7340 | 99.4 | <0.05 | >25 | >500 | 16801428 | |||
| Entecavir | 96.7 | <0.05 | >25 | >500 | 12121928 | |||
| Foscarnet | 94.2 | <0.05 | >25 | >500 | 16280177 | |||
| Rimonabant | 99.4 | 0.23 | >25 | >109 | 31981244 | |||
| Raltitrexed | 93.7 | <0.05 | >25 | >500 | ||||
| Pralatrexate | 101.5 | <0.05 | >25 | >500 | ||||
| Ch 55 | 99.9 | 3.21 | >25 | >7.8 | 30224536 | RAR | ||
| Mevastatin | 100.8 | 2.02 | >25 | >12.4 | 19016777 | Cholesterol synthesis | ||
| Simvastatin | 99.9 | 2.24 | >25 | >11.2 | 19016777 | |||
| Posaconazole | 96.4 | 0.22 | >25 | >114.7 | 19016777 |
%Imax, percent maximum inhibition; CC50, 50% cytotoxic concentration; RAR, retinoic acid receptor; RARβ, retinoic acid receptor beta; TI, therapeutic index.